News & Updates
Showing Pharmacy articles
Showing
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
